Chicago Partners Investment Group LLC Boosts Stake in Johnson & Johnson (JNJ)

Chicago Partners Investment Group LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 68.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,570 shares of the company’s stock after purchasing an additional 4,695 shares during the period. Chicago Partners Investment Group LLC’s holdings in Johnson & Johnson were worth $1,436,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. Lenox Wealth Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the period. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson in the first quarter worth about $186,000. Taylor Wealth Management Partners boosted its holdings in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares during the period. Finally, Puplava Financial Services Inc. acquired a new position in shares of Johnson & Johnson in the second quarter worth about $202,000. Institutional investors own 65.93% of the company’s stock.

Several research analysts have commented on JNJ shares. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Atlantic Securities cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a report on Friday, July 21st. Citigroup Inc. began coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target for the company. Finally, Goldman Sachs Group, Inc. (The) cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their price target for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $143.70.

COPYRIGHT VIOLATION NOTICE: “Chicago Partners Investment Group LLC Boosts Stake in Johnson & Johnson (JNJ)” was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.truebluetribune.com/2017/11/14/chicago-partners-investment-group-llc-boosts-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson (NYSE JNJ) opened at $139.76 on Tuesday. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $144.35. The company has a market cap of $374,930.72, a P/E ratio of 19.55, a PEG ratio of 2.84 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the firm posted $1.68 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is 58.33%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply